Literature DB >> 26265280

Safety analysis of the oncological outcome after vein-preserving surgery for colorectal liver metastases detached from the main hepatic veins.

Federico Tomassini1, Italo Bonadio, Peter Smeets, Karen De Paepe, Giammauro Berardi, Liesbeth Ferdinande, Stéphanie Laurent, Louis J Libbrecht, Karen Geboes, Roberto I Troisi.   

Abstract

PURPOSE: Recent studies have reported that margins alone do not predict survival in patients with a positive chemotherapy response. The aim of this retrospective study is to analyze the surgical and oncological outcomes of patients who underwent chemotherapy and liver resection for colorectal liver metastases (CRLM) with lesions detached from the main hepatic veins, comparing the vein-preserving (VP) approach with traditional surgery.
METHODS: Fourteen patients undergoing VP surgery from January 2006 to January 2013 were matched in a 1:2 ratio with a control group (CG) of 28 patients undergoing traditional resection.
RESULTS: The median follow-up was 43 months. The radiological response was classified as 'partial response' in eight VP patients and 11 controls (57 vs. 39 %, p = 0.249) and as 'stable disease' in three VP patients and 9 controls (21 vs. 32 %, p = 0.465). Ten VP (71.4 %) and twenty CG patients (71.4 %) experienced tumor relapse (p = 0.99). No venous edge recurrences were recorded in the VP group, whereas 1/13 (7.7 %) was observed in the control group (p = 0.99). The pathological response rate was 64 vs. 39 % (p = 0.037) in VP and CG patients, respectively. The 5-year recurrence-free survival rate was 24 % for VP patients and 25 % for CG patients (p = 0.431).
CONCLUSION: In patients with a positive CT response, CRLM can be detached from the hepatic veins, as the oncological outcome is similar to that of a larger resection. The VP approach offers the possibility to enlarge the surgical indications, thus optimizing future surgical treatment chances.

Entities:  

Mesh:

Year:  2015        PMID: 26265280     DOI: 10.1007/s00423-015-1332-9

Source DB:  PubMed          Journal:  Langenbecks Arch Surg        ISSN: 1435-2443            Impact factor:   3.445


  50 in total

1.  Selection of patients for resection of hepatic colorectal metastases: expert consensus statement.

Authors:  Chusilp Charnsangavej; Bryan Clary; Yuman Fong; Axel Grothey; Timothy M Pawlik; Michael A Choti
Journal:  Ann Surg Oncol       Date:  2006-09-01       Impact factor: 5.344

2.  The impact of margins on outcome after hepatic resection for colorectal metastasis.

Authors:  Chandrakanth Are; Mithat Gonen; Kathleen Zazzali; Ronald P Dematteo; William R Jarnagin; Yuman Fong; Leslie H Blumgart; Michael D'Angelica
Journal:  Ann Surg       Date:  2007-08       Impact factor: 12.969

3.  Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial.

Authors:  Bernard Nordlinger; Halfdan Sorbye; Bengt Glimelius; Graeme J Poston; Peter M Schlag; Philippe Rougier; Wolf O Bechstein; John N Primrose; Euan T Walpole; Meg Finch-Jones; Daniel Jaeck; Darius Mirza; Rowan W Parks; Murielle Mauer; Erik Tanis; Eric Van Cutsem; Werner Scheithauer; Thomas Gruenberger
Journal:  Lancet Oncol       Date:  2013-10-11       Impact factor: 41.316

4.  The dimensions of the CRC problem.

Authors:  L V Karsa; T A Lignini; J Patnick; R Lambert; C Sauvaget
Journal:  Best Pract Res Clin Gastroenterol       Date:  2010-08       Impact factor: 3.043

5.  Right portal vein ligation combined with in situ splitting induces rapid left lateral liver lobe hypertrophy enabling 2-staged extended right hepatic resection in small-for-size settings.

Authors:  Andreas A Schnitzbauer; Sven A Lang; Holger Goessmann; Silvio Nadalin; Janine Baumgart; Stefan A Farkas; Stefan Fichtner-Feigl; Thomas Lorf; Armin Goralcyk; Rüdiger Hörbelt; Alexander Kroemer; Martin Loss; Petra Rümmele; Marcus N Scherer; Winfried Padberg; Alfred Königsrainer; Hauke Lang; Aiman Obed; Hans J Schlitt
Journal:  Ann Surg       Date:  2012-03       Impact factor: 12.969

6.  Effect of subcentimeter nonpositive resection margin on hepatic recurrence in patients undergoing hepatectomy for colorectal liver metastases. Evidences from 663 liver resections.

Authors:  J Figueras; F Burdio; E Ramos; J Torras; L Llado; S Lopez-Ben; A Codina-Barreras; S Mojal
Journal:  Ann Oncol       Date:  2007-04-13       Impact factor: 32.976

7.  Clinicopathological features and prognosis in resectable synchronous and metachronous colorectal liver metastasis.

Authors:  Ming-Shian Tsai; Yen-Hao Su; Ming-Chih Ho; Jin-Tung Liang; Tzu-Ping Chen; Hong-Shiee Lai; Po-Huang Lee
Journal:  Ann Surg Oncol       Date:  2006-11-14       Impact factor: 5.344

8.  Genetic and histological assessment of surgical margins in resected liver metastases from colorectal carcinoma: minimum surgical margins for successful resection.

Authors:  Norihiro Kokudo; Yoshio Miki; Sachiko Sugai; Akio Yanagisawa; Yo Kato; Yoshihiro Sakamoto; Junji Yamamoto; Toshiharu Yamaguchi; Tetsuichiro Muto; Masatoshi Makuuchi
Journal:  Arch Surg       Date:  2002-07

9.  One-millimeter cancer-free margin is curative for colorectal liver metastases: a propensity score case-match approach.

Authors:  Zaed Z R Hamady; J Peter A Lodge; Fenella K Welsh; Giles J Toogood; Alan White; Timothy John; Myrddin Rees
Journal:  Ann Surg       Date:  2014-03       Impact factor: 12.969

Review 10.  Expanding criteria for resectability of colorectal liver metastases.

Authors:  Timothy M Pawlik; Richard D Schulick; Michael A Choti
Journal:  Oncologist       Date:  2008-01
View more
  2 in total

1.  Big size is not all, even better!

Authors:  Roberto Ivan Troisi; Mariano Cesare Giglio; Roberto Montalti
Journal:  Hepatobiliary Surg Nutr       Date:  2019-10       Impact factor: 7.293

2.  The single surgeon learning curve of laparoscopic liver resection: A continuous evolving process through stepwise difficulties.

Authors:  Federico Tomassini; Vincenzo Scuderi; Roos Colman; Marco Vivarelli; Roberto Montalti; Roberto Ivan Troisi
Journal:  Medicine (Baltimore)       Date:  2016-10       Impact factor: 1.889

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.